| Mount Sinai School of Medicine and MRC Technology to collaborate on monoclonal antibody production and humanization |
2 April 2012 |
| Mount Sinai Medical Center and MRC Technology have reached an agreement to collaborate on the development of monoclonal antibodies for commercialization as drugs to control infection and treat diseases.. Read in full |
 |
|
| MRC Technology Launches Research Grant Terms Approval Service |
13 March 2012 |
| MRC Technology announces the launch of its research grant terms approval service, with the MS Society receiving the first review.. Read in full |
|
|
| Phosphate Therapeutics acquires novel phosphate binder (PT20) from the Medical Research Council and secures development funding from Inventages Venture Capital for Compound’s Phase 2 Development |
5 March 2012 |
| Phase 2 ready phosphate binder for treatment of hyperphosphataemia. Read in full |
|
|
| MRC Technology to manage intellectual property for AICR |
18 November 2011 |
| MRC Technology to oversee and manage intellectual property arising from AICR-funded projects. Read in full |
|
|
| 1st patient treated with BAN2401 |
6 September 2010 |
| First Alzheimer’s patient treated with BAN2401, a novel antibody targeting the neurotoxin believed to cause Alzheimer’s disease. Read in full |
|
|
| MRC Technology enters into an exclusive license agreement With Genentech |
12 July 2010 |
| MRC Technology and Genentech enter into agreement for series of small molecule drug candidates. The first such programme to come out of MRC Technology.. Read in full |
|
|
| “Skills Swap” to exploit expertise for patient benefit |
7 July 2010 |
| Cancer Research Technology and MRC Technology to ‘swap’ medical discoveries to accelerate the translation of early scientific research into patient benefit.. Read in full |
|
|
| AstraZeneca and MRC Technology form strategic alliance in discovery research, utilising shared compound libraries |
5 July 2010 |
| AstraZeneca share 100,000 compounds with MRC Technology. Read in full |
|
|
| O2h provides multi-FTE -synthetic chemistry services to MRCT |
16 February 2010 |
| O2h will provide multi-FTE -synthetic chemistry services to the drug discovery programmes at MRC Technology. Read in full |
|
|
| MRCT's call for targets |
4 February 2010 |
| Medical Research Council Technology’s Centre for Therapeutics Discovery opens its first ‘Call for Targets’ in an effort to develop drugs in areas of serious unmet need. Read in full |
|
|
| Collaboration between Georg-August-University Göttingen, Universitätsmedizin, the University of Regensburg and MRCT |
12 January 2010 |
| MBM ScienceBridge GmbH negotiates License Agreement between the Georg-August-University Göttingen, Universitätsmedizin, the University of Regensburg, and the UK’s Medical Research Council Technology for a new therapy of inflammatory and immune disease. Read in full |
|
|
| Bicycle Therapeutics is new MRC spinout |
6 October 2009 |
| Bicycle Therapeutics Ltd, a new Medical Research Council (MRC) spin-out, seeking to merge best aspects of small molecules and biologics, secures seed funding from top venture capital firms. Read in full |
|
|
| DiscoveRX GSK and MRCT collaborate to deorphanise GPCRs |
23 September 2009 |
| Industry and academia team up in three-way collaboration to identify natural substances that can bind to orphan G protein-coupled receptors.
Findings could lead to new targets for drug discovery. Read in full |
|
|
| MRC scientists advance understanding of cell death |
13 August 2009 |
| Medical Research Council (MRC) scientists have made an important advance in understanding the biological processes involved when cells are prompted to die.. Read in full |
|
|
| Centre for Therapeutics Discovery |
2 April 2009 |
| MRC and MRC Technology announce new centre for the discovery of novel drugs. Read in full |
|
|
| Heptares secures funding |
24 February 2009 |
| Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets. Read in full |
|
|
| UK Drug Discovery Consortium symposium |
23 February 2009 |
| 1st Annual Symposium of the new UK Drug Discovery Consortium announced for March 11th 2009. Read in full |
|
|
| MRCT Licence Rights to Develop Potential Novel Immunotherapy |
27 January 2009 |
| The Medical Research Council (MRC) & MRC Technology (MRCT) have signed exclusive License and Research Collaboration agreements with Centocor, Inc., which is now known as Centocor Ortho Biotech Inc., for the development of a novel immunotherapy targeting r. Read in full |
|
|
| MRCT and Biolex Therapeutics complete successful collaborations |
14 July 2008 |
| MRC Technology and Biolex Therapeutics successfully complete
collaboration to humanize a novel antibody targeting CD20. Read in full |
|
|
| Intellect Neurosciences and MRCT reach antibody milestone |
25 June 2008 |
| Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) reach important milestone in generating an Alzheimer’s therapeutic antibody. Read in full |
|
|